Right of Reference and License Agreement - Additional Information (Details) - GSK Agreement $ in Millions	6 Months Ended
	Jun. 30, 2023 USD ($) shares
Research And Development Assets Acquired Other Than Through Business Combination [Line Items]
Specified clinical and regulatory milestones	$ 5.0
Specified clinical and regulatory milestones phase two clinical trial	2.5
Maximum
Research And Development Assets Acquired Other Than Through Business Combination [Line Items]
Specified clinical and regulatory milestones	37.5
Specified sales milestone	$ 60.0
Series B Convertible Preferred Stock
Research And Development Assets Acquired Other Than Through Business Combination [Line Items]
Shares issued for asset acquisition | shares	12,500,000